Product
IDO1 Inhibitor BMS-986205
Aliases
BMS986205, BMS 986205, BMS-986205, IDO-1 Inhibitor BMS-986205 (2 other aliases)
2 clinical trials
4 indications
Indication
Hepatocellular CarcinomaIndication
Stage IIIA Hepatocellular CarcinomaIndication
GlioblastomaClinical trial
Phase I/II Trial of BMS-986205 and Nivolumab as First or Second Line Therapy in Hepatocellular CarcinomaStatus: Terminated, Estimated PCD: 2020-11-24
Clinical trial
Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational TrialStatus: Active (not recruiting), Estimated PCD: 2024-02-22